The effect of various types of autoprobiotics on the microbiota and behavior in correction of experimental intestinal dysbiosis

The effect of autoprobiotics, indigenous nonpathogenic enterococci, and the indigenous consortium of microbes (ICM) obtained from fecal samples on the restoration of intestinal microbiocenosis and behavioral responses in male Wistar rats with intestinal dysbiosis induced by ampicillin and metronidazole was studied. The conditions used for fecal sample cultivation led to an increase in the proportion of lactobacilli and enterococci in the ICM. When analyzing the condition of animals, in particular, when evaluating motor and exploratory activity in the “open field” test, as well as the results of 16S rRNA sequencing after administration of autoprobiotics, the following were revealed: faster disappearance of dyspepsia, decreased signs of anxiety, and compensatory changes in the composition of the microbiota. The composition of the intestinal microbiome had significant differences in the animal groups depending on exposure after administration of antimicrobial drugs. Moreover, in the group that did not receive autoprobiotics, along with more pronounced signs of dysbiosis, signs of self-healing were revealed. The maximum changes in the intestinal microbiota and the effect on animal behavior were exerted by ICM. The revealed phenomena should be taken into account when developing methods of complex therapy of diseases accompanied by the development of dysbiotic conditions, especially with pronounced changes in the functioning of the central nervous system.

microbial consortium, enterococci, microbiome, tentative research activity, correlation analysis

1. Lyte M. The microbial organ in the gut as a driver of homeostasis and disease. Medical hypotheses. 2010;74(4):634-638. doi: 10.1016/j.mehy.2009.10.025.

2. Averina O.V., Danilenko V.N. Human intestinal microbiota: role in the formation and functioning of the nervous system. Microbiology. 2017;86(1):5-24. (In Russ.) doi: 10.7868/S0026365617010050.@@ Аверина О.В., Даниленко В.Н. Микробиота кишечника человека: роль в становлении и функционировании нервной системы. Микробиология. 2017;86(1):5-24. doi: 10.7868/S0026365617010050.

3. Kovtun A.S., Averina O.V., Zakharevich N.V., Kasyanov A.S., Danilenko V.N. In silico determination of a metagenomic signature reflecting the neurometabolic potential of the human intestinal microbiota in norm. Genetics. 2018;54(9):1081-1091. (in Russ.)@@ Ковтун А.С., Аверина О.В., Захаревич Н.В., Касьянов А.С., Даниленко В.Н. In silico определение метагеномной сигнатуры, отражающей нейрометаболический потенциал микробиоты кишечника человека в норме. Генетика. 2018;54(9):1081-1091.

4. Bravo J.A., Forsythe P., Chew M.V., Escaravage E., Savignac H.M., Dinan T.G., Bienenstock J., Cryan J.F. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proceedings of the National Academy of Sciences. 2011;108(38):16050-16055. doi: 10.1073/pnas.1102999108.

5. Collins S.M., Michael S., Premysl B. The interplay between the intestinal microbiota and the brain. Nature Reviews Microbiology. 2012;10(11):735-742. doi: 10.1038/nrmicro2876.

6. Messaoudi M., Nicolas V., Jean-François B., Desor D., Javelot H., Rougeot C. Beneficial Psychological Effects of a Probiotic Formulation (Lactobacillus Helveticus R0052 and Bifidobacterium Longum R0175) in Healthy Human Volunteers. Gut Microbes. 2011;2(4):256-261. doi: 10.4161/gmic.2.4.16108.

7. Tillisch K., Labus J., Kilpatrick L. et al. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology. 2013;144(7):1394-1401. doi: 10.1053/j.gastro.2013.02.043.

8. Andreeva I.V., Tolpygo A.V., Andreev, V.A. et al. Psychobiotics: a new way in psychopharmacology, or How do bacteria manage our brain? Clinical microbiology and antimicrobial chemotherapy. 2022;24(2):108-133. (In Russ.) doi: 10.36488/cmac.2022.2.108-133.@@ Андреева И.В., Толпыго А.В., Андреев В.А., Азизов И.С., Гольман И.А., Осипова Н.Н., Привольнев В.В., Стецюк О.У., Соколовская В.В. Психобиотики: новое направление в психофармакологии, или как бактерии влияют на наш мозг? Клиническая микробиология и антимикробная химиотерапия. 2022;24(2):108-133. doi: 10.36488/cmac.2022.2.108-133.

9. Liu W.H., Chuang H.L., Huang Y.T., Wu C.C., Chou G.T., Wang S., Tsai Y.C. Alteration of behavior and monoamine levels attributable to Lactobacillus plantarum PS128 in germ-free mice. Behavioural brain research. 2016;298:202-209.

10. Jiang H., Ling Z., Zhang Y. Mao H. et al. Altered fecal microbiota composition in patients with major depressive disorder. Brain, behavior, and immunity. 2015;48:186-194. doi: 1016/j.bbi.2015.03.016.

11. Messaoudi M., Lalonde R., Violle N. et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. British Journal of Nutrition. 2011;105:755-764.

12. Abdurasulova I.N., Sofonova A.F., Sizov V.V., Kotyleva M.P., Ermolenko E.I. Effect of various probiotics on motor and exploratory activity of rats. Health is the basis of human potential: problems and solutions. Proceedings of the X All-Russian scientific and practical conference with international participation. 2015;10(1):1047-1051. (In Russ.)@@ Абдурасулова И.Н., Софонова А.Ф., Сизов В.В., Котылева М.П., Ермоленко Е.И. Действие различных пробиотиков на двигательную и ориентировочно-исследовательскую активность крыс. Здоровье - основа человеческого потенциала: проблемы и пути их решения. Труды X Всероссийской научно-практической конференции с международным участием. 2015;10(1):1047-1051.

13. Steenbergen L., Sellaro R., van Hemert S. et al. A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood. Brain, behavior, and immunity. 2015;48:258-264. doi:10.1016/j.bbi.2015.04.003.

14. Ermolenko E., Sitkin S., Vakhitov T. et al. Evaluation of the effectiveness of personalised therapy for the patients with irritable bowel syndrome. Beneficial Microbes. 2023;14(2):119-130. doi: 10.3920/BM2022.0053.

15. Bakulina N.V., Tikhonov S.V., Ermolenko E.I. et al. The use of E. faecium probiotic and autoprobiotic in patients with type 2 diabetes mellitus. HERALD of North-Western State Medical University named after II Mechnikov. 2022;14(1):77-88. (In Russ.) doi: 10.17816/mechnikov104795.@@ Бакулина Н.В., Тихонов С.В., Ермоленко Е.И., Котылева М.П., Лаврёнова Н.С., Топалова Ю.Г., Симаненков В.И., Суворов А.Н. Использование пробиотических и аутопробиотических Enterococcus faecium в лечении пациентов с сахарным диабетом 2-го типа. Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2022;14(1):77-88. doi: 10.17816/mechnikov104795.

16. Ilyin V.K., Suvorov A.N., Kiryukhina N.V. et al. Autoprobiotics as a means of preventing infectious and inflammatory diseases in humans in an artificial habitat. Bulletin of the Russian Academy of Medical Sciences, 2013; 68(2): 56-62. (In Russ.)@@ Ильин В.К., Суворов А.Н., Кирюхина Н.В., Усанова Н.А., Старкова Л.В., Бояринцев В.В., Карасева А.Б. Аутопробиотики как средство профилактики инфекционновоспалительных заболеваний у человека в искусственной среде обитания. Вестник Российской академии медицинских наук. 2013;68(2):56-62.

17. Suvorov A., Karaseva A., Kotyleva M. et al. Autoprobiotics as an approach for restoration of personalised microbiota. Frontiers in microbiology. 2018;9:1869. doi: 10.3389/fmicb.2018.01869.

18. Ermolenko E.I., Donetsk V.N., Dmitrieva Yu.V., et al. Effect of probiotic enterococci on functional characteristics of the rat intestine in dysbiosis induced by antibiotics. Bulletin of St. Petersburg University. Medicine. 2009;1:157-167. (In Russ.)@@ Ермоленко Е.И., Донец В.Н., Дмитриева Ю.В. и др. Влияние пробиотических энтерококков на функциональные характеристики кишечника крыс при дисбиозе, индуцированном антибиотиками. Вестник Санкт-Петербургского университета. Медицина. 2009;1:157-167.

19. Ermolenko E.I., Abdurasulova I.N., Kotyleva M.P. et al. Effects of indigenous enterococci on the intestinal microbiota and the behavior of rats on correction of experimental dysbiosis. Neuroscience and Behavioral Physiology. 2018;48(4):496-505. doi: 1007/s11055-018-0591-7.

20. Suvorov A.N., Simanenkov V.I., Sundukova Z.R. et al. Method for producing autoprobiotic of Enterocuccus faecium being representative of indigenic host intestinal microflora. Patent on the application. No 2460778С1, 30.12.2010. (In Russ.)@@ Суворов А.Н., Симаненков В.И., Сундукова З.Р. и др. Способ получения аутопробиотика на основе Enterocuccus faecium, представителя индигенной микрофлоры кишечника хозяина. Патент по заявке No 2460778С1 от 30.12.2010 г.

21. Suvorov A.N., Ermolenko E.I., Kotyleva M.P., Tsapieva A.N. Method for preparing an autoprobiotic based on an anaerobic consortium of bacteria. Patent for invention RU 2734896 C2, 10/26/2020. Application No. 2018147697 dated 12/28/2018. (In Russ.)@@ Суворов А.Н., Ермоленко Е.И., Котылева М.П., Цапиева А.Н. Способ приготовления аутопробиотика на основе анаэробного консорциума бактерий. Патент на изобретение RU 2734896 C2, 26.10.2020. Заявка № 2018147697 от 28.12.2018.

22. Ermolenko E., Gromova L., Borschev Y. et al. Influence of different probiotic lactic acid bacteria on microbiota and metabolism of rats with dysbiosis. Bioscience of microbiota, food and health. 2013; 32(2): 41-49. doi: 10.12938/bmfh.32.41.

23. Ermolenko E., Rybalchenko O., Borshev Y. et al. Influence of monostrain and multistrain probiotics on immunity, intestinal ultrastructure and microbiota in experimental dysbiosis. Beneficial microbes. 2018; 9(6): 937-950. doi: 10.3920/BM2017.0117.

24. Jernberg C., Lofmark S., Edlund C., Jansson J.K. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology. 2010;156(11):3216-3223. doi: 10.1099/mic.0.040618-0.

25. Huang C., Feng S., Huo F., Liu H. Effects of four antibiotics on the diversity of the intestinal microbiota. Microbiology spectrum. 2022;10: e01904-21. doi: 10.1128/spectrum.01904-21.

26. McFarland L.V. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review. BMJ open. 2014;4(8):1-17. doi: 10.1136/bmjopen-2014-005047.

27. Ermolenko E.I., Erofeev N.P., Zakharova L.B., et al. Features of the composition of the intestinal microbiota and motility after correction of experimental dysbiosis with probiotic and autoprobiotic enterococci. Experimental and Clinical Gastroenterology. 2017;7(143):89-96. (In Russ.)@@ Ермоленко Е.И., Ерофеев Н.П., Захарова Л.Б. и др. Особенности состава микробиоты и моторики кишечника после коррекции экспериментального дисбиоза пробиотическими и аутопробиотическими энтерококками. Экспериментальная и клиническая гастроэнтерология. 2017;7(143):89-96.

28. Volkova GS, Serba EM. New Multistrain Bacterial Consortium for Feed Probiotics. Food Processing: Techniques and Technology. 2021;51(2):260-269. (In Russ.) doi: 10.21603/2074-9414-2021-2-260-269.@@ Волкова Г.С., Серба Е.М. Создание многоштаммового бактериального консорциума для технологии пробиотических препаратов кормового назначения. Техника и технология пищевых производств. 2021;51(2): 260-269. doi: 10.21603/2074-9414-2021-2-260-269.

29. Kattel A., Aro V., Lahtvee P.J., Kazantseva J., Jõers A., Nahku R., Belouah. I. Exploring the resilience and stability of a defined human gut microbiota consortium: An isothermal microcalorimetric study. Microbiologyopen. 2024 Aug;13(4): e1430. doi: 10.1002/mbo3.1430.

30. Precup G., Vodnar D.C. Gut Prevotella as a possible biomarker of diet and its eubiotic versus dysbiotic roles: a comprehensive literature review. British Journal of Nutrition. 2019; 122(2):131-140. doi: 10.1017/S0007114519000680.

31. Chang D., Sharma L., Dela Cruz, C.S., Zhang D. Clinical epidemiology, risk factors, and control strategies of Klebsiella pneumoniae infection. Frontiers in microbiology. 2021;12: 750662. doi: 10.3389/fmicb.2021.750662.

32. Arato V., Raso M.M., Gasperini G., Berlanda Scorza F., Micoli F. Prophylaxis and treatment against Klebsiella pneumoniae: current insights on this emerging anti-microbial resistant global threat.International journal of molecular sciences. 2021;22(8):4042. doi: 10.3390/ijms22084042.

33. Russo A., Fusco P., Morrone H.L., Trecarichi E.M., Torti C. New advances in management and treatment of multidrug-resistant Klebsiella pneumoniae. Expert Review of Anti-infective Therapy. 2023;21(1):41-55. doi: 10.1080/14787210.2023.2151435.

34. Hiippala K., Kainulainen V., Kalliomäki M., Arkkila P., Satokari R. Mucosal prevalence and interactions with the epithelium indicate commensalism of Sutterella spp. Frontiers in microbiology. 2016;7:1706. doi: 10.3389/fmicb.2016.01706.

35. Sorouri B., Rodriguez C.I., Gaut B.S., Allison S.D. Variation in Sphingomonas traits across habitats and phylogenetic clades. Frontiers in Microbiology. 2023;14:1146165. doi: 10.3389/fmicb.2023.1146165.

36. Doughari H.J., Ndakidemi P.A., Human I.S., Benade S. The ecology, biology and pathogenesis of Acinetobacter spp.: an overview. Microbes and environments. 2011;26(2): 101-112. doi:10.1264/jsme2.me10179.

37. Gorvitovskaia A., Holmes S.P., Huse S.M.Interpreting Prevotella and Bacteroides as biomarkers of diet and lifestyle. Microbiome. 2016;4(1):15. doi: 10.1186/s40168-016-0160-7.

38. Boyanova L. Cutibacterium acnes (formerly Propionibacterium acnes): friend or foe? Future Microbiology. 2023;18(4): 235-244. doi: 10.2217/fmb-2022-0191.

39. Davari S., Talaei S.A., Alaei H., Salami M. Probiotics treatment improves diabetes-induced impairment of synaptic activity and cognitive function: behavioral and electrophysiological proofs for microbiome-gut-brain axis. Neuroscience. 2013;240:287-296. doi: 10.1016/j.neuroscience.2013.02.055.